Yingpai Pharmaceuticals is dedicated to the research and development of innovative, targeted anticancer drugs with proprietary intellectual property rights, with a particular focus on the synthetic lethality mechanism. Building on its independently developed portfolio targeting the DNA damage response (DDR) pathway, the company has established one of the most comprehensive DDR drug pipelines among global biopharmaceutical firms and is progressively expanding into additional novel synthetic lethality targets. The company's pipeline includes the PARP inhibitor senaparib (IMP4297), the Wee1 inhibitor IMP7068, the ATR inhibitor IMP9064, the PARP1-selective inhibitor IMP1734 (developed in collaboration with U.S.-based Eikon Therapeutics), as well as several other DDR-targeted inhibitors. Among these, the most advanced program, the PARP inhibitor senaparib, is currently undergoing Phase II/III clinical trials globally, including in China, for indications such as ovarian cancer and small-cell lung cancer. The Phase III FLAMES study evaluating senaparib as first-line maintenance therapy in the overall population of patients with advanced ovarian cancer has met its primary endpoint, demonstrating best-in-class efficacy and safety. Based on the FLAMES results, the National Medical Products Administration (NMPA) of China approved the new drug application for senaparib in January 2025. The Wee1 inhibitor IMP7068 and the ATR inhibitor IMP9064 are already in Phase I clinical trials in multiple countries and regions worldwide, including the United States and China, where their recommended Phase II doses (RP2D) have been established. The PARP1-selective inhibitor IMP1734 has received clinical trial approvals from both the FDA and the NMPA and completed enrollment of its first patient in early 2024.